Once valued at $10B, bluebird bio sold to private equity firms for $29M
Private equity firms Carlyle and SK Capital have agreed to pay $29 million to acquire bluebird bio, which has struggled to commercialize three gene therapy products.
Private equity firms Carlyle and SK Capital have agreed to pay $29 million to acquire bluebird bio, which has struggled to commercialize three gene therapy products.
